GSK's "Biotech-In-A-Pharma" R&D Model Makes Progress
Since the mid-2000s, GlaxoSmithKline has been working to rejuvenate its R&D organization, which it believed wasn't sufficiently productive. Industry watchers are gauging progress closely, particularly as the cornerstone of its new approach, the division of GSK's drug discovery operations into nearly 40 specialized and idiosyncratic Drug Performance Units, or DPUs, approaches milestone deadlines in 2011, and as the rest of the industry also struggles with R&D productivity.
You may also be interested in...
The British pharma has financed a new venture fund to create a presence in an emerging technology and help jump-start the fledgling industry because it believes that the science has reached a transition point.
Although GlaxoSmithKline's global sales declined by 10% and EPS rose by 9% during the first quarter, the UK Big Pharma sees signs of increased R&D productivity.
Eli Lilly & Co. gained a foothold in New York with its acquisition of ImClone Systems Inc. in 2008. Now it's looking to make more of a splash in the city and strengthen ties with local academic powerhouses by taking up residence in a new state-of-the-art biotech facility.